Zymeworks rejects ‘unsolicited, opportunistic’ buyout bid by UAE-based All Blue Falcons


Shares of Zymeworks Inc. ZYME, +2.92% rallied 1.5% in morning trading Friday, after the biopharmaceutical company said it rejected the “unsolicited, opportunistic, non-binding” $10.50-per-share buyout bid by activist investor All Blue Falcons FZE. The company said it determined that the bid by the UAE-based investment holding company “significantly undervalues” the company and its prospects, and “lacks credibility” by offering no information regarding funding. The stock had soared 23.2% on April 29, three days after closing at a record low, after the company confirmed it had received the bid from All Blue Falcons for $10.50 in cash. The stock had rallied to a post-bid high of $7.15 on May 3, which was 31.9% below the bid price, before pulling back. The stock was recently trading 43.7% below the bid price. The stock has plunged 63.9% year to date, while the iShares Biotechnology ETF IBB, +0.50% has dropped 24.3% and the S&P 500 SPX, +0.01% has lost 17.5%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Airbnb hosts use income from the platform to pay for food, rent and mortgages — but these 3 U.S. states are more lucrative than others
Next articleMarket Snapshot: U.S. stocks end mixed, but book weekly losses as Dow suffers longest losing streak since 1932


Please enter your comment!
Please enter your name here